Tilray Brands, Inc. (TLRY)
USD 0.45
(-5.84%)
USD 0.45
(-5.84%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 | -72.84 Million USD | 91.81% |
| 2023 | -889.52 Million USD | -142.8% |
| 2022 | -246.4 Million USD | 786.85% |
| 2021 | -218.35 Million USD | -54.92% |
| 2020 | -18.39 Million CAD | 367.85% |
| 2019 | -36.66 Million CAD | 2062.99% |
| 2018 | -658 Thousand CAD | -116.73% |
| 2017 | 4.37 Million CAD | 4014.4% |
| 2016 | 115.11 Thousand CAD | 97.8% |
| 2015 | -5.06 Million CAD | -11068.29% |
| 2014 | -1.43 Million CAD | 53.98% |
| 2013 | -608.47 Thousand CAD | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 FY | - USD | 112.32% |
| 2024 Q1 | -7.63 Million USD | 82.14% |
| 2024 Q2 | -4.1 Million USD | -17.69% |
| 2024 Q3 | -552 Thousand USD | -774.69% |
| 2024 Q4 | 11.13 Million USD | 113.41% |
| 2023 Q4 | -6.94 Million USD | 86.95% |
| 2023 Q3 | -53.21 Million USD | -38.69% |
| 2023 FY | - USD | -142.8% |
| 2023 Q1 | 733 Thousand USD | -99.76% |
| 2023 Q2 | -38.36 Million USD | -5334.24% |
| 2022 Q3 | 50.04 Million USD | 630.78% |
| 2022 Q4 | 299.37 Million USD | 498.25% |
| 2022 FY | - USD | 786.85% |
| 2022 Q2 | -9.42 Million USD | 65.77% |
| 2022 Q1 | -27.54 Million USD | -408.64% |
| 2021 Q4 | 8.92 Million USD | 137.29% |
| 2021 Q1 | 31.67 Million CAD | -35.35% |
| 2021 Q2 | -69.23 Million CAD | -318.6% |
| 2021 Q3 | -23.93 Million CAD | 65.43% |
| 2021 FY | - USD | -54.92% |
| 2020 Q3 | 38.96 Million CAD | -5.61% |
| 2020 FY | - CAD | 367.85% |
| 2020 Q1 | 23.97 Million CAD | -42.83% |
| 2020 Q4 | 48.98 Million CAD | 25.71% |
| 2020 Q2 | 41.28 Million CAD | 72.17% |
| 2019 Q3 | -15.53 Million CAD | -157.12% |
| 2019 Q2 | 27.2 Million CAD | 1099.34% |
| 2019 Q1 | -2.72 Million CAD | -186.01% |
| 2019 FY | - CAD | 2062.99% |
| 2019 Q4 | 41.94 Million CAD | 369.97% |
| 2018 Q1 | -4.53 Million CAD | -296.77% |
| 2018 Q3 | -298.02 Thousand CAD | -134.15% |
| 2018 Q4 | 3.16 Million CAD | 1161.9% |
| 2018 FY | - CAD | -116.73% |
| 2018 Q2 | 872.63 Thousand CAD | 119.26% |
| 2017 Q3 | -4.6 Million CAD | -597.14% |
| 2017 Q4 | 2.3 Million CAD | 150.0% |
| 2017 FY | - CAD | 4014.4% |
| 2017 Q1 | 1.05 Million CAD | 260.92% |
| 2017 Q2 | 926.49 Thousand CAD | -12.58% |
| 2016 Q1 | -291.38 Thousand CAD | 20.26% |
| 2016 FY | - CAD | 97.8% |
| 2016 Q4 | 293.63 Thousand CAD | 155.3% |
| 2016 Q3 | 115.01 Thousand CAD | 147.38% |
| 2016 Q2 | -242.73 Thousand CAD | 16.7% |
| 2015 Q2 | -6482.23 CAD | 22.05% |
| 2015 Q1 | -8316.12 CAD | 86.85% |
| 2015 FY | - CAD | -11068.29% |
| 2015 Q4 | -365.43 Thousand CAD | 84.96% |
| 2015 Q3 | -2.42 Million CAD | -37386.56% |
| 2014 Q1 | -7855.65 CAD | -73.67% |
| 2014 Q3 | -47.23 Thousand CAD | -933.36% |
| 2014 Q4 | -63.26 Thousand CAD | -33.93% |
| 2014 FY | - CAD | 53.98% |
| 2014 Q2 | -4571.06 CAD | 41.81% |
| 2013 FY | - CAD | 0.0% |
| 2013 Q2 | -20.45 Thousand CAD | -49.81% |
| 2013 Q3 | -13.33 Thousand CAD | 34.84% |
| 2013 Q4 | -4523.23 CAD | 66.07% |
| 2013 Q1 | -13.65 Thousand CAD | 24.11% |
| 2012 Q2 | -3424.37 CAD | 0.0% |
| 2012 Q3 | -65.73 Thousand CAD | -1819.75% |
| 2012 Q4 | -17.99 Thousand CAD | 72.63% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Collegium Pharmaceutical, Inc. | 308.32 Million USD | 123.625% |
| China SXT Pharmaceuticals, Inc. | -2.35 Million USD | -2998.37% |
| Embecta Corp. | 245.4 Million USD | 129.683% |
| Pacira BioSciences, Inc. | 162.89 Million USD | 144.717% |
| PainReform Ltd. | -9.56 Million USD | -661.239% |
| Sunshine Biopharma, Inc. | -3.82 Million USD | -1804.682% |
| SCYNEXIS, Inc. | 73.47 Million USD | 199.134% |
| Journey Medical Corporation | 1.92 Million USD | 3891.931% |
| Safety Shot Inc | -12.18 Million USD | -497.8% |
| Alpha Teknova, Inc. | -25.53 Million USD | -185.223% |
| Bright Green Corporation | - USD | Infinity% |
| Procaps Group, S.A. | 104.02 Million USD | 170.023% |
| Alvotech | -484.86 Million USD | 84.977% |
| ANI Pharmaceuticals, Inc. | 109.32 Million USD | 166.633% |
| Aquestive Therapeutics, Inc. | 1.18 Million USD | 6262.69% |
| Cosmos Health Inc. | -17.06 Million USD | -326.936% |
| Dynavax Technologies Corporation | 9.66 Million USD | 853.6% |
| Esperion Therapeutics, Inc. | -150.1 Million USD | 51.473% |
| Intra-Cellular Therapies, Inc. | -158.85 Million USD | 54.144% |
| Sunshine Biopharma, Inc. | -3.82 Million USD | -1804.682% |
| Theratechnologies Inc. | -10.31 Million USD | -606.336% |
| Harrow Health, Inc. | 9.72 Million USD | 849.182% |
| Sonoma Pharmaceuticals, Inc. | -4.52 Million USD | -1509.79% |
| Biofrontera Inc. | -18.45 Million USD | -294.749% |
| DURECT Corporation | -24.68 Million USD | -195.102% |
| Supernus Pharmaceuticals, Inc. | 98.26 Million USD | 174.131% |
| Cronos Group Inc. | -72.14 Million USD | -0.962% |
| OptiNose, Inc. | -15.55 Million USD | -368.353% |
| Ironwood Pharmaceuticals, Inc. | -924.86 Million USD | 92.124% |
| Kala Pharmaceuticals, Inc. | -36.08 Million USD | -101.882% |
| RedHill Biopharma Ltd. | 26.26 Million USD | 377.327% |
| Organogenesis Holdings Inc. | 36.03 Million USD | 302.168% |
| Guardion Health Sciences, Inc. | -3.92 Million USD | -1757.125% |
| Cumberland Pharmaceuticals Inc. | -710.85 Thousand USD | -10147.31% |
| Radius Health, Inc. | 38.31 Million USD | 290.141% |
| Universe Pharmaceuticals INC | -3.21 Million USD | -2165.675% |
| ProPhase Labs, Inc. | -14.82 Million USD | -391.286% |
| Phibro Animal Health Corporation | 84.6 Million USD | 186.096% |
| Procaps Group S.A. | 104.02 Million USD | 170.023% |
| TherapeuticsMD, Inc. | -8.4 Million USD | -767.075% |
| Viatris Inc. | 3.51 Billion USD | 102.071% |
| Rockwell Medical, Inc. | -4.69 Million USD | -1451.832% |
| Aytu BioPharma, Inc. | -1.01 Million USD | -7097.925% |
| SIGA Technologies, Inc. | 84.15 Million USD | 186.554% |
| Lifecore Biomedical, Inc. | 812 Thousand USD | 9070.813% |
| Shineco, Inc. | -26.55 Million USD | -174.321% |
| PetIQ, Inc. | 81.48 Million USD | 189.393% |
| Regencell Bioscience Holdings Limited | -3.61 Million USD | -1913.557% |
| Incannex Healthcare Limited | -18.5 Million USD | -293.661% |
| Neurocrine Biosciences, Inc. | 416.1 Million USD | 117.506% |
| Alimera Sciences, Inc. | 7.27 Million USD | 1101.141% |
| Silver Spike Investment Corp. | 7.34 Million USD | 1092.397% |
| Assertio Holdings, Inc. | -222.44 Million USD | 67.254% |
| Shuttle Pharmaceuticals Holdings, Inc. | -3.99 Million USD | -1725.342% |
| Petros Pharmaceuticals, Inc. | -4.21 Million USD | -1629.469% |
| Clever Leaves Holdings Inc. | -16.8 Million USD | -333.486% |
| Cyclo Therapeutics, Inc. | -20.03 Million USD | -263.655% |
| Avadel Pharmaceuticals plc | -149.12 Million USD | 51.153% |
| Hempacco Co., Inc. | -12.77 Million USD | -470.277% |
| Talphera, Inc. | -9.84 Million USD | -640.124% |
| Alvotech | -484.86 Million USD | 84.977% |
| Eagle Pharmaceuticals, Inc. | 77.5 Million USD | 193.989% |
| Lantheus Holdings, Inc. | 491 Million USD | 114.835% |
| Currenc Group, Inc. | -1.9 Million USD | -3732.684% |
| Kamada Ltd. | 21.53 Million USD | 438.27% |
| Indivior PLC | 66 Million USD | 210.368% |
| Evoke Pharma, Inc. | -7.29 Million USD | -898.904% |
| Flora Growth Corp. | -45.87 Million USD | -58.803% |
| Cyclo Therapeutics, Inc. | -20.03 Million USD | -263.655% |
| Evolus, Inc. | -41.81 Million USD | -74.224% |
| HUTCHMED (China) Limited | 25.52 Million USD | 385.346% |
| Amphastar Pharmaceuticals, Inc. | 241.46 Million USD | 130.167% |
| Akanda Corp. | -27.73 Million USD | -162.633% |